Checkpoint Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accounts Payable and Accrued Expenses

3 Months Ended

Mar. 31, 2020

Note 7 - Accounts Payable and Accrued Expenses

At March 31, 2020 and December 31, 2019, accounts payable and accrued expenses consisted of the following ($ in thousands):


	March 31,		December 31,
	2020		2019
Accounts payable	$	2,314	$	3,079
Accrued compensation		122		414
Research and development		3,088		3,496
Other		315		268
Accounts payable and accrued expenses - related party		1,149		862
Total accounts payable and accrued expenses	$	6,988	$	8,119